Sarasota, Florida, U.S., October 7, 2026
Lakewood-Amedex Biotherapeutics has announced positive preclinical data supporting the potential of its Bisphosphocin® class of antimicrobial compounds in urinary tract infections (UTIs) and pulmonary infections. The findings include animal-model data showing that intravesical administration of Nu-8 achieved up to 97% inhibition of E. coli growth in rodents infected with the bacterium compared with a vehicle control. The company is developing Bisphosphocin compounds as a novel class of fast-acting, broad-spectrum antimicrobials aimed at infectious diseases involving drug-resistant pathogens. Additional preclinical findings reported by the company indicate activity against a range of resistant bacterial and fungal organisms in pulmonary infection models, supporting continued investigation of the platform as Lakewood-Amedex seeks to address challenges associated with antimicrobial resistance (AMR).
Nu-8 Shows Activity in Urinary Tract Infection Model
In a preclinical urinary tract infection model, Lakewood-Amedex evaluated intravesical administration of Bisphosphocin compound Nu-8 in rodents infected with Escherichia coli. The company reported that a 10% solution of Nu-8 produced up to 97% inhibition of E. coli growth, while the vehicle control group showed no effect. The findings are particularly relevant to complicated urinary tract infections, including catheter-associated urinary tract infections, which can involve drug-resistant bacteria and bacterial biofilms. According to the company, the Bisphosphocin class has also demonstrated in vitro activity against resistant organisms commonly associated with UTIs, including E. coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. The compounds have additionally shown activity against biofilm-forming organisms, an area of interest in infections where bacterial communities can contribute to persistent disease and treatment challenges.
Bisphosphocin Compounds Show Pulmonary Infection Activity
Lakewood-Amedex also reported in vivo activity in pulmonary infection animal models following administration of Bisphosphocin compounds as an aerosol formulation. The compounds demonstrated activity in models involving Acinetobacter species, P. aeruginosa and Aspergillus fumigatus. The company said the Bisphosphocin class has also shown in vitro activity against several resistant organisms frequently associated with pulmonary infections, including Haemophilus influenzae, K. pneumoniae and P. aeruginosa. Pulmonary infections such as community-acquired, hospital-acquired and ventilator-associated bronchial pneumonia can involve drug-resistant bacteria, while people with cystic fibrosis may experience recurrent bacterial and fungal lung infections. These preclinical findings expand the range of infectious disease indications being investigated for the Bisphosphocin platform and provide additional data for selecting potential candidates for future clinical development.
Advertisement
Lakewood-Amedex Advances Antimicrobial Pipeline
The new findings add to Lakewood-Amedex’s broader development strategy focused on fast-acting, broad-spectrum antimicrobials designed to address infections involving antibiotic-resistant pathogens. The company said Bisphosphocin compounds possess characteristics including rapid antimicrobial activity and broad-spectrum effects, while it is continuing research to identify the most suitable candidate for early clinical development. The lead Bisphosphocin candidate Nu-3, formulated as a topical gel, is currently being evaluated in an ongoing Phase 2a clinical trial for mildly infected diabetic foot ulcers (iDFU), with topline results expected in the first quarter of 2027. The company is also investigating different Bisphosphocin compounds and formulations across infectious disease applications. However, the newly reported UTI and pulmonary findings are preclinical, and results observed in animal models or in vitro studies may not predict outcomes in humans. The company continues to face the usual development, regulatory and clinical uncertainties associated with investigational antimicrobial therapies. The reported data nevertheless provide additional evidence supporting continued evaluation of the Bisphosphocin platform and its potential role in addressing the growing challenge of antimicrobial resistance and difficult-to-treat infections.
Source: Lakewood-Amedex Biotherapeutics Labs press release
